United States Uterine Fibroids Treatment Devices Market By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment), By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Others), By Region and Competition, Forecast & Opportunities, 2020-2030F

Market Overview

United States Uterine Fibroids Treatment Devices Market was valued at USD 512.35 Million in 2024 and is expected to reach USD 776.73 Million by 2030 with a CAGR of 7.38% during the forecast period. The United States uterine fibroids treatment devices market is experiencing steady growth, driven by rising awareness of minimally invasive procedures, technological advancements, and an increasing prevalence of uterine fibroids among women of reproductive age. As healthcare providers and patients seek effective, non-invasive, and patient-friendly treatment options, the demand for advanced uterine fibroids treatment devices continues to rise.

Uterine fibroids, also known as leiomyomas, affect a significant percentage of women in the U.S., particularly those between the ages of 30 and 50. The growing number of diagnosed cases has led to an increased demand for advanced treatment options, ranging from surgical interventions to minimally invasive therapies.

While minimally invasive procedures offer numerous advantages, the high cost of treatment devices and associated procedures remains a barrier to widespread adoption. The initial investment required for advanced technologies such as MRgFUS and robotic-assisted surgery may limit accessibility, particularly in smaller healthcare facilities.

Key Market Drivers

Growth in Healthcare Industry

The expanding healthcare industry in the United States is a key driver of the uterine fibroids treatment devices market, fueled by increasing healthcare expenditures, advancements in medical technology, and growing patient awareness. In 2022, healthcare expenditures in the United States accounted for approximately 17.8% of the nation’s Gross Domestic Product (GDP), considerably exceeding the 11.5% average among other high-income countries. Coverage varies significantly across the population, with certain groups—such as the elderly, disabled, and low-income individuals—receiving more comprehensive care through government programs like Medicaid and Medicare. As healthcare infrastructure improves and access to specialized treatments expands, the demand for innovative and minimally invasive solutions for uterine fibroids is rising significantly.

One of the primary factors contributing to market growth is the increasing prevalence of uterine fibroids among women in the U.S. According to the Office on Women's Health (OWH), nearly 20% to 80% of women develop fibroids by the age of 50, creating a strong demand for effective treatment options. With healthcare providers prioritizing patient-centered care, there is a shift toward minimally invasive and non-surgical treatment devices, such as uterine artery embolization (UAE), magnetic resonance-guided focused ultrasound (MRgFUS), and laparoscopic radiofrequency ablation (RFA). Magnetic resonance-guided focused ultrasound (MRgFUS) is an innovative, non-invasive technology in functional neurosurgery. By utilizing geometric focusing of high-intensity ultrasound through the intact skull, it precisely targets deep brain tissue without the need for anesthesia or exposure to ionizing radiation, while enabling real-time monitoring. Beyond thermal ablation, MRgFUS facilitates the reversible opening of the blood-brain barrier (BBB) and enables neuromodulation, offering significant therapeutic potential for a range of neurological disorders. These advanced treatment modalities offer reduced recovery times, fewer complications, and improved patient outcomes, making them increasingly preferred over traditional surgical methods like hysterectomy.

Surge in Technological Advancements

The increasing adoption of laparoscopic and robotic-assisted myomectomy has transformed uterine fibroid treatment by offering greater precision, reduced surgical trauma, and faster recovery times. UC Davis Health surgeons are nationally recognized for their expertise in robotic-assisted surgery, a cutting-edge advancement in minimally invasive surgical technology. This innovative approach is available across multiple specialties, including gastrointestinal, cardiothoracic, gynecologic oncology, otolaryngology (head and neck), and urologic surgery. Robotic-assisted procedures, such as those performed using the da Vinci Surgical System, have enhanced surgeons' ability to remove fibroids with minimal invasiveness, leading to higher patient preference for these advanced options.

Additionally, the growing use of non-invasive therapies like HIFU (High-Intensity Focused Ultrasound) has provided an alternative to traditional surgery. HIFU leverages ultrasound waves to thermally ablate fibroids without incisions, significantly reducing patient discomfort and hospital stays. The increasing availability of FDA-approved HIFU systems is contributing to their rising adoption in the U.S. market.    

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Treatment Devices

Advanced treatment devices such as magnetic resonance-guided focused ultrasound (MRgFUS), robotic-assisted surgical systems, and radiofrequency ablation (RFA) devices require sophisticated technology, contributing to high manufacturing and acquisition costs. These devices incorporate precision-engineered components, high-intensity imaging systems, and AI-driven controls, making them significantly more expensive than traditional surgical instruments. As a result, many healthcare facilities, particularly smaller hospitals and outpatient centers, may struggle to afford these technologies.

The cost of procedures using advanced devices is another major barrier. While minimally invasive treatments offer shorter recovery times and reduced hospital stays, the upfront costs of using MRgFUS, uterine artery embolization (UAE), or RFA can be considerably higher than traditional surgical options like hysterectomy or myomectomy. These costs often translate into higher out-of-pocket expenses for patients, particularly those with limited insurance coverage for newer treatment modalities.

Key Market Trends

Growing Awareness and Early Diagnosis

The increasing awareness of uterine fibroids and the growing emphasis on early diagnosis are shaping a key trend in the U.S. uterine fibroids treatment devices market. The Early Detection Research Group (EDRG) provides support for research aimed at evaluating the effectiveness, operational performance, and clinical impact—including both risks and advantages—of cancer early detection technologies and methodologies, such as advanced imaging techniques and molecular biomarker-based approaches. As educational initiatives, patient advocacy programs, and advancements in diagnostic technologies continue to expand, more women are seeking early medical intervention, driving demand for innovative and less invasive treatment options.

One of the primary factors contributing to this trend is the widespread dissemination of information regarding uterine fibroids and their symptoms. Public health campaigns, medical organizations, and digital health platforms are playing a crucial role in educating women about the condition, leading to higher diagnosis rates. Organizations such as the Fibroid Foundation and the Society for Women’s Health Research (SWHR) are actively working to raise awareness about available treatment options, encouraging women to seek medical evaluation at earlier stages of the condition.

Segmental Insights

Mode of Treatment Insights

Based on Mode of Treatment, Minimally Invasive Treatment have emerged as the fastest growing segment in the United States Uterine Fibroids Treatment Devices Market in 2024. Many women, particularly those in their reproductive years, seek uterus-preserving treatment options to maintain fertility and avoid the long recovery periods associated with hysterectomy. Minimally invasive procedures, such as laparoscopic myomectomy and radiofrequency ablation (RFA), allow fibroid removal while preserving the uterus, making them a preferred choice among patients and healthcare providers.

Technology Insights

Based on Technology, Surgical Techniques have emerged as the fastest growing segment in the United States Uterine Fibroids Treatment Devices Market during the forecast period. One of the primary drivers behind the growth of surgical techniques is the widespread adoption of minimally invasive surgical (MIS) procedures such as laparoscopic myomectomy, hysteroscopic myomectomy, and robotic-assisted surgeries. Compared to traditional open surgeries, these techniques offer significant advantages, including smaller incisions, shorter hospital stays, and faster recovery times. As a result, more patients are opting for minimally invasive procedures over conventional hysterectomy, leading to a surge in demand for advanced surgical devices.  

Download Free Sample Report

Regional Insights

Based on Region, Midwest have emerged as the dominating region in the United States Uterine Fibroids Treatment Devices Market in 2024. The Midwest has a large patient population affected by uterine fibroids, particularly among African American women, who are disproportionately impacted by the condition. The rising number of diagnosed cases has driven demand for effective and minimally invasive treatment options, boosting the market for uterine fibroids treatment devices.

Recent Development

• In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the launch of its SMART OS 2.4 software technology for the Sonata System. This advanced system integrates the first and only intrauterine ultrasound technology with a proprietary radiofrequency ablation device, offering a non-invasive, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. Affecting up to 80% of women under 50, uterine fibroids can now be treated using the Sonata System’s radiofrequency energy, which targets and ablates fibroids from within the uterus without requiring surgical incisions. This innovative approach presents a groundbreaking alternative to more invasive procedures, such as hysterectomy and myomectomy.
• In 2024, Gynesonics, Inc., a privately held medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced that the American Medical Association (AMA), with the support of the American College of Obstetrics and Gynecology (ACOG), has introduced a new Category I Current Procedural Terminology (CPT) code—58580—for transcervical uterine fibroid ablation using radiofrequency under ultrasound guidance. The AMA CPT Editorial Panel determined that this procedure meets the criteria for a Category I designation, as it aligns with current medical practices and has demonstrated clinical efficacy in published literature that meets AMA CPT standards.
• In October 2024, Hologic, Inc., a global leader in women’s health, announced that it had entered into a definitive agreement to acquire Gynesonics, Inc., a privately held medical device company specializing in minimally invasive solutions for women’s health. The acquisition, valued at approximately USD 350 million, is subject to working capital and customary closing adjustments. Headquartered in Redwood City, California, Gynesonics develops and markets the Sonata System, an innovative technology designed for diagnostic intrauterine imaging and the transcervical treatment of certain symptomatic uterine fibroids, including those causing heavy menstrual bleeding. The Sonata System integrates real-time intrauterine ultrasound guidance with targeted radiofrequency ablation, enabling a non-incisional procedure.
• In January 2025, Profound Medical Corp., a commercial-stage medical device company specializing in the development and commercialization of customizable, incision-free ablation therapies for diseased tissue, reported its preliminary unaudited revenue results for the fourth quarter and full year 2024. Additionally, the company is advancing the commercialization of TULSA-PRO, an innovative technology that integrates real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential to become a widely adopted treatment across the entire prostate disease spectrum. This includes patients with low-, intermediate-, and high-risk prostate cancer; those with both prostate cancer and benign prostatic hyperplasia (BPH); individuals with BPH alone; as well as patients requiring salvage therapy for radio-recurrent localized prostate cancer.

Key Market Players

• Medtronic Plc
• Stryker Corporation
• Boston Scientific Corporation
• INSIGHTEC Ltd.
• CooperSurgical Inc.

Report Scope

In this report, the United States Uterine Fibroids Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Uterine Fibroids Treatment Devices Market, By Mode of Treatment:

o   Invasive Treatment

o   Minimally Invasive Treatment

o   Non-invasive Treatment

• United States Uterine Fibroids Treatment Devices Market, By Technology:

o   Surgical Techniques

o   Laparoscopic Techniques

o   Ablation Techniques

o   Others

• United States Uterine Fibroids Treatment Devices Market, By Region:

o   Northeast

o   Midwest

o   South

o   West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Uterine Fibroids Treatment Devices Market.

Available Customizations:

United States Uterine Fibroids Treatment Devices Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United States Uterine Fibroids Treatment Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com